SUPPLEMENT
Q1 2023 — Other Financial Disclosures
Q1 2023PDF · 16 pages469 KB
1 2 3 - 8 11 12 13 14 15 Table 1: Sales by Segment Table 2: Sales by Geographic Area Table 3: Sales of Key Products/Franchises Table 3a: Supplemental Sales Reconciliation Table 3b: Supplemental Sales Information Table 4: Condensed Consolidated Statement of Earnings - QTD Table 5: Non-GAAP Adjusted Operational Sales Growth - QTD Table 6: Non-GAAP Adjusted Net Earnings Table 7: Non-GAAP IBT by Segment - QTD Table 8: Non-GAAP P&L Reconciliation First Quarter 2023 Other Financial Disclosures Table of Contents 10 9 -- 1 of 16 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) 2023 2022 Total Operations Currency Sales to customers by segment of business Consumer Health U.S. 1,735 $ 1,557 11.4 % 11.4 - International 2,117 2,029 4.4 11.3 (6.9) 3,852 3,586 7.4 11.3 (3.9) Pharmaceutical (1) U.S. 7,023 6,632 5.9 5.9 - International 6,390 6,237 2.4 8.6 (6.2) 13,413 12,869 4.2 7.2 (3.0) Pharmaceutical excluding COVID-19 Vaccine (1) U.S. 7,023 6,557 7.1 7.1 - International 5,643 5,855 (3.6) 2.4 (6.0) 12,666 12,412 2.0 4.9 (2.9) MedTech (1) U.S. 3,759 3,225 16.6 16.6 - International 3,722 3,746 (0.6) 6.2 (6.8) 7,481 6,971 7.3 11.0 (3.7) U.S. 12,517 11,414 9.7 9.7 - International 12,229 12,012 1.8 8.3 (6.5) Worldwide 24,746 23,426 5.6 9.0 (3.4) U.S. 12,517 11,339 10.4 10.4 - International 11,482 11,630 (1.3) 5.2 (6.5) Worldwide excluding COVID-19 Vaccine (1) 23,999 $ 22,969 4.5 % 7.7 (3.2) Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. (1) Refer to supplemental sales reconciliation schedule FIRST QUARTER Percent Change Page 1 of 15 -- 2 of 16 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) 2023 2022 Total Operations Currency Sales to customers by geographic area U.S. 12,517 $ 11,414 9.7 % 9.7 - Europe 6,332 6,024 5.1 10.0 (4.9) Western Hemisphere excluding U.S. 1,587 1,482 7.1 14.3 (7.2) Asia-Pacific, Africa 4,310 4,506 (4.3) 4.1 (8.4) International 12,229 12,012 1.8 8.3 (6.5) Worldwide 24,746 $ 23,426 5.6 % 9.0 (3.4) Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. FIRST QUARTER Percent Change Page 2 of 15 -- 3 of 16 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER 2023 2022 Reported Operational (1) Currency CONSUMER HEALTH SEGMENT (2) OTC US 745 $ 670 11.0% 11.0% - Intl 897 791 13.5% 19.8% -6.3% WW 1,642 1,461 12.4% 15.8% -3.4% SKIN HEALTH / BEAUTY US 617 544 13.4% 13.4% - Intl 493 468 5.3% 12.6% -7.3% WW 1,110 1,012 9.7% 13.1% -3.4% ORAL CARE US 159 143 11.6% 11.6% - Intl 202 223 -9.6% -4.0% -5.6% WW 361 366 -1.3% 2.1% -3.4% BABY CARE US 96 85 13.0% 13.0% - Intl 263 270 -2.8% 4.5% -7.3% WW 359 355 1.0% 6.5% -5.5% WOMEN'S HEALTH US 3 3 1.8% 1.8% - Intl 214 224 -4.9% 4.1% -9.0% WW 217 228 -4.8% 4.1% -8.9% WOUND CARE / OTHER US 115 112 2.6% 2.6% - Intl 49 52 -6.0% 2.3% -8.3% WW 164 164 -0.1% 2.5% -2.6% TOTAL CONSUMER HEALTH US 1,735 1,557 11.4% 11.4% - Intl 2,117 2,029 4.4% 11.3% -6.9% WW 3,852 $ 3,586 7.4% 11.3% -3.9% See footnotes at end of schedule % Change Page 3 of 15 -- 4 of 16 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER PHARMACEUTICAL SEGMENT (2,3) 2023 2022 Reported Operational (1) Currency IMMUNOLOGY US 2,448 $ 2,501 -2.1% -2.1% - Intl 1,664 1,617 2.9% 9.7% -6.8% WW 4,112 4,119 -0.2% 2.5% -2.7% REMICADE US 276 358 -22.8% -22.8% - US Exports (4) 41 80 -48.8% -48.8% - Intl 170 225 -24.4% -20.0% -4.4% WW 487 663 -26.5% -25.0% -1.5% SIMPONI / SIMPONI ARIA US 271 287 -5.6% -5.6% - Intl 266 283 -6.1% 1.8% -7.9% WW 537 571 -5.8% -1.9% -3.9% STELARA US 1,451 1,379 5.2% 5.2% - Intl 993 909 9.3% 16.2% -6.9% WW 2,444 2,288 6.8% 9.6% -2.8% TREMFYA US 406 391 3.9% 3.9% - Intl 234 199 17.3% 24.9% -7.6% WW 640 590 8.4% 11.0% -2.6% OTHER IMMUNOLOGY US 3 6 -51.2% -51.2% - Intl 0 0 - - - WW 3 6 -51.3% -51.3% 0.0% INFECTIOUS DISEASES US 392 461 -14.9% -14.9% - Intl 1,193 836 42.8% 49.2% -6.4% WW 1,586 1,297 22.3% 26.4% -4.1% COVID-19 VACCINE US 0 75 * * - Intl 747 382 95.6% * -8.9% WW 747 457 63.4% 70.8% -7.4% EDURANT / rilpivirine US 9 9 -1.4% -1.4% - Intl 271 239 13.4% 18.7% -5.3% WW 280 248 12.8% 18.0% -5.2% PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 378 369 2.5% 2.5% - Intl 99 132 -25.2% -21.2% -4.0% WW 477 501 -4.8% -3.7% -1.1% OTHER INFECTIOUS DISEASES US 5 8 -33.1% -33.1% - Intl 77 83 -7.6% -5.6% -2.0% WW 82 91 -9.8% -8.0% -1.8% % Change Page 4 of 15 -- 5 of 16 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER 2023 2022 Reported Operational (1) Currency NEUROSCIENCE US 978 843 16.0% 16.0% - Intl 826 898 -8.1% -3.1% -5.0% WW 1,804 1,741 3.6% 6.1% -2.5% CONCERTA / Methylphenidate US 70 35 * * - Intl 136 122 11.4% 20.2% -8.8% WW 206 157 31.4% 38.2% -6.8% INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA US 713 661 7.9% 7.9% - Intl 331 387 -14.6% -8.9% -5.7% WW 1,044 1,048 -0.4% 1.7% -2.1% SPRAVATO US 111 61 82.4% 82.4% - Intl 20 9 * * * WW 131 70 86.9% 88.0% -1.1% OTHER NEUROSCIENCE US 84 86 -3.5% -3.5% - Intl 339 380 -10.7% -7.6% -3.1% WW 423 467 -9.4% -6.9% -2.5% ONCOLOGY US 1,889 1,582 19.4% 19.4% - Intl 2,223 2,369 -6.1% -0.1% -6.0% WW 4,112 3,950 4.1% 7.7% -3.6% CARVYKTI US 70 - * * - Intl 2 - * * - WW 72 - * * - DARZALEX US 1,191 953 25.0% 25.0% - Intl 1,072 903 18.8% 26.4% -7.6% WW 2,264 1,856 22.0% 25.7% -3.7% ERLEADA US 249 206 21.2% 21.2% - Intl 293 194 50.9% 60.7% -9.8% WW 542 400 35.6% 40.3% -4.7% IMBRUVICA US 270 370 -27.1% -27.1% - Intl 557 668 -16.6% -11.7% -4.9% WW 827 1,038 -20.3% -17.2% -3.1% ZYTIGA / abiraterone acetate US 16 19 -14.0% -14.0% - Intl 229 520 -56.0% -52.2% -3.8% WW 245 539 -54.5% -50.9% -3.6% OTHER ONCOLOGY US 92 34 * * - Intl 70 84 -17.2% -12.1% -5.1% WW 162 118 37.4% 41.0% -3.6% % Change Page 5 of 15 -- 6 of 16 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER 2023 2022 Reported Operational (1) Currency PULMONARY HYPERTENSION US 600 572 4.9% 4.9% - Intl 272 279 -2.7% 5.3% -8.0% WW 872 852 2.4% 5.0% -2.6% OPSUMIT US 273 273 -0.1% -0.1% - Intl 167 170 -1.6% 6.1% -7.7% WW 440 443 -0.7% 2.3% -3.0% UPTRAVI US 304 269 13.1% 13.1% - Intl 58 56 3.3% 9.4% -6.1% WW 362 325 11.4% 12.4% -1.0% OTHER PULMONARY HYPERTENSION US 23 30 -22.4% -22.4% - Intl 47 53 -12.6% -1.8% -10.8% WW 70 83 -16.1% -9.3% -6.8% CARDIOVASCULAR / METABOLISM / OTHER US 715 672 6.3% 6.3% - Intl 212 238 -10.8% -6.3% -4.5% WW 927 910 1.8% 3.0% -1.2% XARELTO US 578 508 13.7% 13.7% - Intl - - - - - WW 578 508 13.7% 13.7% - OTHER US 137 164 -16.7% -16.7% - Intl 212 238 -10.8% -6.3% -4.5% WW 349 402 -13.2% -10.5% -2.7% TOTAL PHARMACEUTICAL US 7,023 6,632 5.9% 5.9% - Intl 6,390 6,237 2.4% 8.6% -6.2% WW 13,413 $ 12,869 4.2% 7.2% -3.0% See footnotes at end of schedule % Change Page 6 of 15 -- 7 of 16 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER MEDTECH SEGMENT (2,3) 2023 2022 Reported Operational (1) Currency INTERVENTIONAL SOLUTIONS US 863 $ 494 74.5% 74.5% - Intl 640 597 7.1% 14.9% -7.8% WW 1,503 1,092 37.6% 41.9% -4.3% ELECTROPHYSIOLOGY US 571 470 21.4% 21.4% - Intl 522 532 -1.8% 6.1% -7.9% WW 1,092 1,002 9.1% 13.3% -4.2% ABIOMED US 264 - * * - Intl 60 - * * - WW 324 - * * - OTHER INTERVENTIONAL SOLUTIONS US 28 24 17.4% 17.4% - Intl 58 65 -11.7% -5.0% -6.7% WW 87 90 -3.9% 1.1% -5.0% ORTHOPAEDICS US 1,363 1,289 5.8% 5.8% - Intl 881 899 -2.0% 4.0% -6.0% WW 2,245 2,188 2.6% 5.1% -2.5% HIPS US 241 225 7.3% 7.3% - Intl 149 164 -9.0% -3.6% -5.4% WW 390 389 0.4% 2.7% -2.3% KNEES US 226 201 12.4% 12.4% - Intl 142 138 3.4% 9.6% -6.2% WW 368 339 8.7% 11.3% -2.6% TRAUMA US 491 475 3.2% 3.2% - Intl 267 273 -2.4% 3.6% -6.0% WW 757 748 1.2% 3.4% -2.2% SPINE, SPORTS & OTHER US 406 387 4.7% 4.7% - Intl 323 324 -0.3% 5.9% -6.2% WW 729 712 2.4% 5.2% -2.8% % Change Page 7 of 15 -- 8 of 16 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER 2023 2022 Reported Operational (1) Currency SURGERY US 975 921 5.9% 5.9% - Intl 1,459 1,513 -3.6% 3.1% -6.7% WW 2,434 2,434 0.0% 4.1% -4.1% ADVANCED US 444 417 6.5% 6.5% - Intl 673 729 -7.6% -1.1% -6.5% WW 1,118 1,146 -2.5% 1.6% -4.1% GENERAL US 531 504 5.4% 5.4% - Intl 785 784 0.2% 7.0% -6.8% WW 1,316 1,288 2.2% 6.4% -4.2% VISION US 558 521 7.1% 7.1% - Intl 743 736 0.8% 8.0% -7.2% WW 1,300 1,257 3.4% 7.6% -4.2% CONTACT LENSES / OTHER US 444 400 11.1% 11.1% - Intl 509 511 -0.3% 7.9% -8.2% WW 953 910 4.7% 9.3% -4.6% SURGICAL US 114 121 -6.0% -6.0% - Intl 233 226 3.3% 8.0% -4.7% WW 347 347 0.1% 3.1% -3.0% TOTAL MEDTECH US 3,759 3,225 16.6% 16.6% - Intl 3,722 3,746 -0.6% 6.2% -6.8% WW 7,481 $ 6,971 7.3% 11.0% -3.7% * Percentage greater than 100% or not meaningful (1) Operational growth excludes the effect of translational currency (2) Unaudited (3) Certain prior year amounts have been reclassified to conform to current year product disclosures; refer to supplemental sales schedules (4) Reported as U.S. sales % Change Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely Page 8 of 15 -- 9 of 16 -- 2023 2022 Total Operations Currency Pharmaceutical U.S. 7,023 $ 6,632 5.9 % 5.9 - International 6,390 6,237 2.4 8.6 (6.2) Worldwide 13,413 12,869 4.2 7.2 (3.0) COVID-19 Vaccine U.S. 0 75 * * - International 747 382 95.6 * (8.9) Worldwide 747 457 63.4 70.8 (7.4) Pharmaceutical excluding COVID-19 Vaccine U.S. 7,023 6,557 7.1 7.1 - International 5,643 5,855 (3.6) 2.4 (6.0) Worldwide 12,666 12,412 2.0 4.9 (2.9) Worldwide U.S. 12,517 11,414 9.7 9.7 - International 12,229 12,012 1.8 8.3 (6.5) Worldwide 24,746 23,426 5.6 9.0 (3.4) COVID-19 Vaccine U.S. 0 75 * * - International 747 382 95.6 * (8.9) Worldwide 747 457 63.4 70.8 (7.4) Worldwide U.S. 12,517 11,339 10.4 10.4 - International 11,482 11,630 (1.3) 5.2 (6.5) Worldwide excluding COVID-19 Vaccine 23,999 $ 22,969 4.5 % 7.7 (3.2) Note: Columns and rows within tables may not add due to rounding * Percentage greater than 100% or not meaningful Supplemental Sales Reconciliation (Unaudited) (Dollars in Millions) FIRST QUARTER Percent Change Page 9 of 15 -- 10 of 16 -- Full Year Q1 Q2 Q3 Q4 Full Year PHARMACEUTICAL SEGMENT (1) NEUROSCIENCE SPRAVATO US 198 61 74 88 105 328 INTL 26 9 11 12 14 46 WW 224 70 85 100 119 374 OTHER NEUROSCIENCE (2) US 427 86 93 106 91 376 INTL 1,647 380 341 286 351 1,358 WW 2,074 467 433 393 442 1,734 ONCOLOGY CARVYKTI US - - 24 55 54 133 INTL - - - - - - WW - - 24 55 54 133 OTHER ONCOLOGY US 110 34 33 37 52 156 INTL 458 84 72 64 63 283 WW 568 118 106 100 114 438 CARDIOVASCULAR / METABOLISM / OTHER OTHER (3) US 754 164 148 147 110 569 INTL 927 238 215 198 194 845 WW 1,682 402 363 345 304 1,414 MEDTECH SEGMENT (1) INTERVENTIONAL SOLUTIONS ELECTROPHYSIOLOGY US 1,730 470 499 520 547 2,036 INTL 1,893 532 469 453 447 1,901 WW 3,623 1,002 968 973 994 3,937 ABIOMED (4) US - - - - 31 31 INTL - - - - - - WW - - - - 31 31 OTHER INTERVENTIONAL SOLUTIONS US 106 24 26 27 25 102 INTL 242 65 56 60 48 230 WW 348 90 81 87 73 332 Note: Columns and rows within tables may not add due to rounding (1) Unaudited (2) Other Neuroscience is inclusive of RISPERDAL CONSTA, which was previously disclosed separately (3) Other is inclusive of INVOKANA, which was previously disclosed separately (4) Acquired on December 22, 2022 Supplemental Sales Information (Dollars in Millions) Certain prior year amounts have been reclassified to conform to current year product disclosures 2021 2022 2022 Page 10 of 15 -- 11 of 16 -- Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers 24,746 $ 100.0 23,426 $ 100.0 5.6 Cost of products sold 8,395 33.9 7,598 32.4 10.5 Gross Profit 16,351 66.1 15,828 67.6 3.3 Selling, marketing and administrative expenses 6,138 24.8 5,938 25.4 3.4 Research and development expense 3,563 14.4 3,462 14.8 2.9 In-process research and development 49 0.2 610 2.6 Interest (income) expense, net (20) (0.1) (12) (0.1) Other (income) expense, net 7,228 29.2 (102) (0.4) Restructuring 130 0.6 70 0.3 Earnings/(Loss) before provision for taxes on income (737) (3.0) 5,862 25.0 (112.6) Provision for/(Benefit from) taxes on income (669) (2.7) 713 3.0 (193.8) Net earnings/(Loss) (68) $ (0.3) 5,149 $ 22.0 (101.3) Net earnings/(Loss) per share (Basic/Diluted)* (0.03) $ 1.93 $ (101.6) Average shares outstanding (Basic/Diluted)* 2,605.5 2,666.5 Effective tax rate 90.8 % 12.2 % Adjusted earnings before provision for taxes and net earnings (1) Earnings before provision for taxes on income 8,468 $ 34.2 8,218 $ 35.1 3.0 Net earnings 7,068 $ 28.6 7,129 $ 30.4 (0.9) Net earnings per share (Diluted) 2.68 $ 2.67 $ 0.4 Average shares outstanding (Diluted)** 2,634.3 2,666.5 Effective tax rate 16.5 % 13.3 % * Basic shares are used to calculate loss per share as use of diluted shares when in a loss position would be anti-dilutive. ** Difference of 28.8 shares due to anti-dilutive impact on net loss position. (1) See Reconciliation of Non-GAAP Financial Measures. FIRST QUARTER 2023 2022 Page 11 of 15 -- 12 of 16 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Consumer Health Pharmaceutical MedTech Total WW As Reported 7.4% 4.2% 7.3% 5.6% U.S. 11.4% 5.9% 16.6% 9.7% International 4.4% 2.4% (0.6)% 1.8% WW Currency (3.9) (3.0) (3.7) (3.4) U.S. - - - - International (6.9) (6.2) (6.8) (6.5) WW Operational 11.3% 7.2% 11.0% 9.0% U.S. 11.4% 5.9% 16.6% 9.7% International 11.3% 8.6% 6.2% 8.3% Abiomed (4.6) (1.4) U.S. (8.2) (2.3) International (1.6) (0.5) All Other Acquisitions and Divestitures 0.0 0.0 0.0 0.0 U.S. 0.0 0.0 0.0 0.0 International 0.0 0.2 0.0 0.1 WW Adjusted Operational 11.3% 7.2% 6.4% 7.6% U.S. 11.4% 5.9% 8.4% 7.4% International 11.3% 8.8% 4.6% 7.9% Adjusted Operational Sales Growth FIRST QUARTER 2023 ACTUAL vs. 2022 ACTUAL Segments Note: Percentages are based on actual, non-rounded figures and may not sum Page 12 of 15 -- 13 of 16 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures (Dollars in Millions Except Per Share Data) 2023 2022 Net Earnings/(Loss), after tax- as reported ($68) $5,149 Pre-tax Adjustments Litigation expense 6,900 - Intangible Asset Amortization expense 1,204 1,108 COVID-19 Vaccine related costs 1 444 - Consumer Health separation costs 300 102 Restructuring related2 130 72 (Gains)/losses on securities 72 411 Medical Device Regulation3 64 60 IPR&D 49 610 Acquisition, integration and divestiture related 42 - Other - (7) Tax Adjustments Tax impact on special item adjustments 4 (2,057) (393) Consumer Health separation tax related costs 11 96 Tax legislation and other tax related (23) (79) Adjusted Net Earnings, after tax $7,068 $7,129 Average shares outstanding (Diluted) 2,634.3 2,666.5 Adjusted net earnings per share (Diluted) $2.68 $2.67 Operational adjusted net earnings per share (Diluted) $2.75 1 2 3 4 First Quarter Notes: COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's completion of its COVID-19 vaccine contractual commitments. In the first quarter of 2023, the company completed a prioritization of its research and development (R&D) investment within the Pharmaceutical segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, HIV and hepatitis. The restructuring expenses of $130 million in the quarter include the termination of partnered and non-partnered program costs and asset impairments. European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance which is expected to be completed during 2024. The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. Page 13 of 15 -- 14 of 16 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2023 2022 2023 2022 2023 2022 2023 2022 2023 2022 2023 2022 Reported Income Before Tax by Segment $ 776 686 4,444 3,924 1,445 1,477 (7,102) (123) (300) (102) (737) 5,862 % to Sales 20.1% 19.1% 33.1% 30.5% 19.3% 21.2% -28.7% -0.5% -1.2% -0.4% -3.0% 25.0% Intangible asset amortization expense 82 94 739 760 383 254 - - 1,204 1,108 In-process research and development - 610 49 - - - 49 610 Litigation related 6,900 - - 6,900 - COVID-19 Vaccine related costs - - 444 - - - - - - - 444 - Loss/(gain) on securities - 38 394 34 17 - - 72 411 Restructuring related 14 130 (14) 72 - - 130 72 Acquisition, integration and divestiture related - - 42 - - - 42 - Medical Device Regulation - - 64 60 - - 64 60 Consumer Health separation costs - - - - 300 102 300 102 Other - - - (7) - - (7) Adjusted Income Before Tax by Segment $ 858 794 5,795 5,674 2,017 1,880 (202) (130) - - 8,468 8,218 % to Sales 22.3% 22.1% 43.2% 44.1% 27.0% 27.0% -0.8% -0.6% 0.0% 0.0% 34.2% 35.1% Q1 YTD - Income Before Tax by Segment Dollars in Millions Consumer Health Pharmaceutical MedTech Unallocated Worldwide Total Consumer Health Separation Costs Page 14 of 15 -- 15 of 16 -- First Quarter Acquistion, integration First Quarter April 2, 2023 GAAP Intangible asset amortization Litigation related Restructuring related and divestiture related Medical Device Regulation Other April 2, 2023 Non-GAAP Cost of products sold 8,395 $ (1,200) - (23) (206) (12) 6,954 Selling, marketing and admin expenses 6,138 (7) (38) 6,093 Research and development expense 3,563 (16) (34) (16) (2) 3,495 Other (Income) / Expense 7,228 (4) (6,900) - (26) (72) (222) (285) - (281) In-process research and development 49 (49) - Interest (Income) / Expense (20) 37 17 Restructuring 130 (130) - Provision for/(Benefit from) taxes on income (669) 194 1,622 11 32 5 16 12 105 60 (11) 23 - 1,400 Net Earnings/(Loss) (68) 1,010 5,278 38 98 37 56 52 339 240 11 (23) - 7,068 First Quarter Acquistion, integration First Quarter April 3, 2022 GAAP Intangible asset amortization Litigation related Restructuring related and divestiture related Medical Device Regulation Other April 3, 2022 Non-GAAP Cost of products sold 7,598 $ (1,108) (16) (22) 6,452 Selling, marketing and admin expenses 5,938 (6) 5,932 Research and development expense 3,462 (32) 3,430 Other (Income) / Expense (102) - - 14 - (411) - (102) 7 (594) In-process research and development 610 (610) - Restructuring 70 (70) - Provision for taxes on income 713 168 (53) 138 12 - 96 11 - 23 (96) 79 (2) 1,089 Net Earnings 5,149 940 53 472 60 - 315 49 - 79 96 (79) (5) 7,129 Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Consumer Health separation tax related costs In-process research and development (Loss)/gain on securities COVID-19 Vaccine Related Costs Consumer Health separation costs Tax legislation and other tax related Consumer Health separation tax related costs In-process research and development (Loss)/gain on securities COVID-19 Vaccine Related Costs Consumer Health separation costs Tax legislation and other tax related Page 15 of 15 -- 16 of 16 --